Update on the treatment of ankylosing spondylitis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 6, 2007, Pages 1125-1133

  Maksymowych, Walter P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adalimumab; Ankylosing spondylitis; Etanercept; Infliximab; NSAIDs

Indexed keywords

ADALIMUMAB; CELECOXIB; DICLOFENAC; ETANERCEPT; ETORICOXIB; INFLIXIMAB; KETOPROFEN; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; SALAZOSULFAPYRIDINE; STROMELYSIN;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; GRANULOMATOSIS; HUMAN; INFECTION; INJECTION SITE REACTION; IRIDOCYCLITIS; JOINT DESTRUCTION; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIC ULCER BLEEDING; PROGNOSIS; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SPINE RADIOGRAPHY; THROMBOSIS;

EID: 38049151458     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Askling J, Fored CM, Geborek P, et al. 2006. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis, 65:707-12.
2. Askling J, Fored CM, Baecklund E, et al. 2005. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis, 64:1414-20.
3. Askling J, Fored CM, Brandt L, et al. 2005. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis, 64:1421-6.
4. Baraliakos X, Davis J, Tsuji W, et al. 2005. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum, 52:1216-23.
5. Baraliakos X, Listing J, Brandt J, et al. 2005. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3-years of continuous treatment with infliximab. Arthritis Res Therapy, 7:R439-4.
6. Baughman RP, Drent M, Kavuru M, et al. 2006. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med, 174:795-802.
7. Baughnian RP, Lower EE, Bradley DA, et al. 2005. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest, 128:1062-47.
8. Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295:2275-85.
9. Braun J, Baraliakos X, Brandt J, et al. 2005. Persistent clinical response to the anti-TNF-a antibody infliximab in patients with ankylosing spondylitis over 3-years. Rheumatol, 44:670-6.
10. Braun J, Baraliakos X, Golder W, et al. 2003. Improvement of spinal inflammation in ankylosing spondylitis (AS) by infliximab therapy as assessed by magnetic resonance imaging (MRI) using a novel evaluated spinal scoring system. Arthritis Rheum, 48:1126-36.
11. Braun J, Baraliakos X, Listing J, et al. 2005. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum, 52:2447-53.
12. Braun J, Brandt J, Listing J, et al. 2002. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet, 359:1187-93.
13. Braun J, Landewe R, Hermann KG, et al. 2006. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum, 54:1646-52.
14. Braun J, Pham T, Sieper J, et al. 2003. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis, 62:817-24.
15. Braun J, Zochling J, Baraliakos X, et al. 2006. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis, 65:1147-53.
16. Breban M, Ravaud P, Claudepierre P, et al. 2005. No superiority of infliximab (INF) plus methotrexate (MTX) over INF alone in the treatment of ankylosing spondylitis (AS): results of a one-year randomized prospective study. Arthritis Rheum, 52 Suppl:498.
17. Chen J, Liu C. 2006. Is sulphasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol, 33:722-31.
18. Clegg DO, Reda DJ, Weisman MH, et al. 1996. Comparison of sulfasalazine and placebo in the treatment of ankylsoing spondylitis. Arthritis Rheum, 39:2004-12.
19. Cobo-Ibáñez T, Muñoz-Fernández S, Bohorquez-Heras C, et al. 2006. New acute anterior uveitis flares in patients with spondyloarthropathies treated with TNF blockers. Arthritis Rheum, 54(Suppl 9): 1118.
20. Creemers MCW, Franssen MJAM, van't Hof MA, et al. 1994. A radiographic scoring system and identification of variables measuring structural damage in ankylosing spondylitis [thesis]. Nijmegen, The Netherlands: University of Nijmegen.
21. Davis JC, van der Heijde D, Braun J, et al. 2003. Recombinant human tumor necrosis factor receptor (Etanercept) for treating ankylosing spondylitis. Arthritis Rheum, 48:3230-6.
22. Davis JC, van der Heijde DM, Braun J, et al. 2005. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96-weeks. Ann Rheum Dis, 64:1557-62.
23. Davis JC Jr, Van tier Heijde DM, Dougados M, et al. 2005. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. Journal of Rheumatol, 32:1751-4.
24. Dixon WG, Watson K, Lunt M, et al. 2006. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum, 54:23 68-76.
25. Dougados M, van der Linden S, Leirisalo-Repo M, et al. 1995. Sulfasalazine in the treatment of spondyloarthropathy. Arthritis Rheum, 38:618-27.
26. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, et al. 2006. Development of sarcoidosis during etanercept therapy. Arthritis Rheum, 55:817-20.
27. Guignard S, Gossec L, Salliot C, et al. 2006. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis, 65:1631-4.
28. Haibel H, Rudwaleit M, Brandt HC, et al. 2006. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum, 54:678-81.
29. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. 2006. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterol, 130:323-33.
30. Inman RD, Shojania K, Keystone E, et al. 2006. Efficacy of lower dose infliximab in active ankylosing spondylitis - interim results of a Canadian study. Arthritis Rheum, 54(Suppl 9):S471.
31. Jacobsson LT, Turesson C, Gulfe A, et al. 2005. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol, 32: 1213-18.
32. Lambert RGW, Salonen D, Rahman P, et al. 2006. Adalimumab reduces spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis (AS) - 52-week magnetic resonance imaging (MRI) results from The Canadian AS Study. Ann Rheum Dis, 65(Suppl 11):65.
33. Listing J, Strangfeld A, Kary, et al. 2005. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum, 52:3403-12.
34. Maksymowych WP, Inman RD, Gladman D, et al. 2003. Canadian Rheumatology Association consensus on the use of anti-TNF(-directed therapies in the treatment of spondyloarthritis. J Rheumatol, 30:1356-63.
35. Maksymowych WP, Inman RD, Salonen D, et al. 2005a. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum, 53:502-9.
36. Maksymowych WP, Inman RD, Salonen D, et al. 2005b. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum, 53:703-9.
37. Maksymowych WP, Landewé R, Conner-Spady B, et al. 2006. Serum Matrix Metalloproteinase 3 is an Independent Predictor of Structural Damage Progression in Patients with Ankylosing Spondylitis (AS). Arthritis Rheum, 54(Suppl 9):S512.
38. Maksymowych WP, Patra K, Inman RD, et al. 2005. Adalimumab suppresses biomarkes of cartilage degradation in active ankylosing spondylitis - results of the Canada AS study. Arthritis Rheum, 53(Suppl 9):L6.
39. Maksymowych WP, Poole AR, Hiebert L, et al. 2005. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol, 32:1911-7.
40. Maksymowych WP, Rahman P, Keystone E. 2005. Efficacy of adalimumab in active ankylosing spondylitis (AS) (Results of the Canadian AS Study. Arthritis Rheum, 52(Suppl):S217.
41. Neal B, Rodgers A, Dunn L, Fransen M. 2000. Non-steroidal antiinflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev, 3:CD001160.
42. Nissila M, Lehtinen K, Leirisalo-Repo M, et al. 1988. Sulfasalazine in the treatment of ankylosing spondylitis. Arthritis Rheum, 31:1111-16.
43. Oh J, Arkfeld DG, Horwitz DA. 2005. Development of Crohn's disease in a patient taking etanercept. J Rheumatol, 32:752-3.
44. Pham T, Landewe R, van der Linden S, et al. 2006. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis, 65:1620-5.
45. Rudwaleit M, Listing J, Brandt J, et al. 2004. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor a blockers in ankylosing spondylitis. Ann Rheum Dis, 63:665-70.
46. Sandborn WJ, Hanauer SB, Katz S, et al. 2001. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterol, 121:1088-94.
47. Setoguchi S, Solomon DH, Weinblatt ME, et al. 2006. Tumornecrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum, 54:2757-64.
48. Siegle I, Klein T, Backman JT, et al. 1998. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum, 41:122-9.
49. Targan SR, Hanauer SB, van Deventer SJ, et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Enl J Med, 337: 1029-35.
50. Utz JP, Limper AH, Kalra S, et al. 2003. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest, 124:177-85.
51. van der Heijde D, Baraf HSB, Ramos-Remus C, et al. 2005. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis. Arthritis Rheum, 52:1205-15.
52. van der Heijde D, Dijkmans B, Geusens P, et al. 2005. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized placebo-controlled trial (ASSERT). Arthritis Rheum, 52:582-91.
53. van der Heijde D, Kivitz A, et al. 2006. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 54:2136-46.
54. van der Heijde D, Landewe R, van der Linden S. 2005. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured, Arthritis Rheum, 52:1979-85.
55. van der Heijde DM, Landewe R, Ory P, et al. 2006. Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis, 65(Suppl II):81.
56. van der Heijde DMFM, Wanders A, Mielants H, et all. 2004. Prediction of progression of radiographic damage over 4-years in patients with ankylosing spondylitis. Ann Rheum Dis, 63:OP132.
57. Wanders A, van der Heijde D, Landewe R, et al. 2005. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum, 52:1756-65.
58. Wanders AJB, Landewe' RBM, Spoorenberg A, et al. 2004. What is the most appropriate radiologic scoring method for ankylosing spondylitis. Arthritis Rheum, 50:2622-32.
59. Zhang X, Schwarz EM, Young DA, et al. 2002. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest, 109:1405-15.